ReviewFrontiers in immunology2025
Unveiling CD177: a key player in tumors, autoimmune diseases, and inflammatory disorders.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Biodegradable molybdenum intramedullary nails facilitate fracture repair through neutrophil-mediated immune response.Materials today. Bio · 2026Article
- A multimodal predictive model incorporating transcriptomic-guided blood biomarkers and clinical variables for sepsis-associated acute kidney injury.Renal failure · 2026Article
- Identification of novel sepsis-related neutrophil subsets and surface markers for clinical diagnosis and outcome.Virulence · 2026Article
- Cellular heterogeneity of hepatic granuloma formation and evolution in murine schistosomiasis japonica.Nature communications · 2026Article
- Detection and Identification of Anti-Neutrophil Antibodies in Immune Neutropenia: Integrating Serology, Genotyping and Clinical Interpretation.Antibodies (Basel, Switzerland) · 2026Review
- Cellular and Molecular Profiling of Native Heart Valves in Infective Endocarditis: A Comparative Study with Calcific Aortic Valve Disease.Biomedicines · 2026Article
- Chrysin Pretreatment Enhances BMSC Therapeutic Efficacy in Resolving Diabetic Wound Healing.Biomedicines · 2026Article
- Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases.International journal of molecular sciences · 2026Article
- Spatial organization of neutrophil and macrophage populations in surgically treated hepatocellular carcinoma: a practical tissue-based immunophenotyping study.Frontiers in immunology · 2026Article
- Neutrophil extracellular traps associated with severity and prognosis of community-acquired pneumonia.Clinical and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD177, also referred to as human neutrophil antigen NB1 or polycythemia rubra vera-1, is a glycosylphosphatidylinositol-anchored glycoprotein with a molecular weight of approximately 58-64 kDa, predominantly expressed in neutrophils, neutrophilic myelocytes, and metamyelocytes. While extensive research has focused on the role of CD177 in neutrophils, where it is implicated in transendothelial migration, cellular viability, and bactericidal activities, its functions outside of neutrophils remain largely unexplored. Under inflammatory conditions, CD177 expression on neutrophils is significantly upregulated, facilitating their migration to sites of inflammation. CD177
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.